European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis
For Trade and Medical Media Only
Mundipharma today announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adult patients. The MAA is based on results from the pivotal ReSTORE Phase III clinical trial, which demonstrated statistical non-inferiority of rezafungin dosed once weekly when compared to the current standard of care, caspofungin, dosed once daily. This trial provides evidence of efficacy and safety of rezafungin as potential first-line treatment for candidemia and invasive candidiasis.1
Invasive candidiasis is a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues.2 Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%.3 There is a real need for new treatment options to address this serious disease, especially as there has been no significant progress in treatment over the last decade.
“Rezafungin, as a next generation echinocandin, represents the first advancement in the treatment of invasive Candida infections in a very long time. If approved, the treatment could bring new hope for critically ill, vulnerable patients battling with this deadly disease in the EU,“ said Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma. “We are pleased that the EMA has accepted our marketing authorisation application for rezafungin, and we look forward to working with the EMA to bring this medicine to patients.”
Rezafungin has already been granted Orphan Drug Designation for its use in the treatment of invasive candidiasis in both the EU and US.4,5 A New Drug Application was recently submitted to the US Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis the USA. The FDA has previously identified rezafungin as a Qualified Infectious Disease Product (QIDP), which grants both Fast Track and Priority Review status.
Cidara has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.
About Invasive Candidiasis
Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is as high as 40%.3 IC is characterised as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues, known as candidemia and deep-seated tissue candidiasis.2
About Rezafungin
Rezafungin is a next-generation, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara has completed a Phase III clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial).6
In this ReSTORE trial, rezafungin met the primary endpoint for the European Medicines Agency (EMA) Marketing Authorization Application (MAA) submission of global cure at Day 14, and also met the primary endpoint for the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission of all-cause mortality at Day 30. Both of these results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, which is the current standard of care. Rezafungin was generally well tolerated and had a similar safety profile to caspofungin.6
Cidara is also currently conducting a second Phase III clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
About Mundipharma
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centered around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
SciA-RZF-2200053
Date of preparation: August 2022
References
1 Thompson, G.R. et al, ReSTORE: Efficacy and Safety Results of the Phase 3, Noninferiority Trial of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis, Abstract presented at ECCMID 2022
2 Cortes JA, Corrales IF. Invasive Candidiasis: Epidemiology and Risk Factors. November 2018. Available at https://www.intechopen.com/chapters/64365. Last accessed June 2022.
3 Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015;373:1445-1456.
4 U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=%20507215 . Last accessed July 2022
5 European Commission. Community Register of orphan medicinal products. Available at: https://ec.europa.eu/health/documents/community-register/html/o2385.htm. Last accessed July 2022.
6 Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis. Available at https://www.mundipharma.com/Mundipharma-and-Cidara-Therapeutics-Announce-First-Presentation-of-Results-from-Global-Phase-3-ReSTORE-Trial-of-Rezafungin-for-Treatment-of-Candidemia-and/or-Invasive-Candidiasis-Demonstrating-its-Positive-Efficacy-and-Safety-Profile
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005377/en/
Contact information
MEDIA CONTACT
Jan Milton-Edwards
Mundipharma
+44-7341-739-984
jan.milton-edwards@mundipharma.com
Tara Lanigan
Mundipharma
+44-7918-970301
tara.lanigan@mundipharma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WELOCK and ApartX Ink Key China-Kazakhstan Digital Trade Agreement at Global Digital Trade Expo4.10.2024 03:54:00 CEST | Press Release
On September 25th, the 3rd Global Digital Trade Expo “Digital Trade Night” was held in Hangzhou. The event highlighted important digital trade projects between China and Kazakhstan, injecting constant momentum into economic and trade cooperation between the two sides. During the event, the much-anticipated signing ceremony for the “China-Kazakhstan Digital Trade Key Project” was officially launched. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003595967/en/ (Photo: Business Wire) Important witnesses of the signing ceremony included: Zhaslan Madiyev (Minister) Ministry of Digital Development, Innovations and Aerospace Industry of the Republic of Kazakhstan Yao Gaoyuan Mayor of Hangzhou Avazhan Mukanova (Director of the Department of International Cooperation) Ministry of Digital Development, Innovations and Aerospace Industry of the Republic of Kazakhstan Shuang Dehui Deputy Director General of Guangdong Provincial Depar
Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art3.10.2024 18:01:00 CEST | Press Release
Saudi traditional arts are set to reach new global audiences as the Royal Institute of Traditional Arts (Wrth) participates in the Saudi Cultural Week in Greece from September 27 to October 1. The event, titled “The Heritage of Two Cultures," explores Saudi heritage through the lens of "Al-Qatt Al-Asiri" art. Wrth offers a series of interactive workshops, including a highlight on the creation of natural dyes and gypsum carving arts with workshops and hands-on community artworks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003645976/en/ Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art (Photo: AETOSWire) As part of Culture Week, five talented Saudi artists lead interactive workshops showcasing the art of gypsum carving with traditional ‘Asiri’ patterns. This unique art form gained international recognition after being inscribed on UNESCO's Intangible Cultural Herit
Experience the Future of Smarter AI for All at Lenovo’s Tenth Annual Global Tech World Event3.10.2024 15:40:00 CEST | Press Release
On October 15, 2024, Lenovo will host its annual global innovation event, Tech World, in Bellevue, Washington. This marks the 10th consecutive year of the event and reflects a decade of innovation and transformation from the company. This year’s event will explore how Lenovo is delivering on the promise of artificial intelligence (AI) with end-to-end solutions fueling its mission of Smarter AI for All. Technology featured will include ground-breaking AI for Good projects, hybrid AI to empower both individuals and enterprises, and proven ways to fast-track and deploy generative AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003339216/en/ What's next for AI? Join us October 15, 2024 at #LenovoTechWorld to hear top industry leaders discuss the future of AI innovation for all. Learn more: https://lnv.gy/3ZxcPr5 (Graphic: Business Wire) The company will also discuss its ongoing investment and collaboration with partners to
The Estée Lauder Companies’ NIV and TikTok Announce the Winners of The Catalysts Program3.10.2024 15:02:00 CEST | Press Release
The Estée Lauder Companies (NYSE: EL) (“ELC”) is pleased to announce the winners for The Catalysts program. Created by ELC’s New Incubation Ventures (“NIV”) and launched with support from TikTok, the integrated, global initiative is aimed at spotlighting, uplifting, and empowering emerging storytellers with fresh visions for the beauty industry. The program underscores NIV's dedication to championing trailblazing spirits in beauty, accentuating the influence and impact of the beauty industry and its interconnectedness with wider cultural, social, and artistic landscapes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003679516/en/ The Estée Lauder Companies’ NIV and TikTok announce the winners of The Catalysts Program (Graphic: Business Wire) On October 2, 2024, founders of the nine finalist companies including Baude NY, BEAME, LOVERBOY BEAUTY, Etia London, Forta, Gorgeous Nothings, Ruka, Sky High Farm Universe, and Zure
Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations3.10.2024 15:00:00 CEST | Press Release
Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/ Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire) AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom